CytomX Therapeutics has revealed initial treatment using CX-2051, a selective EpCAM-targeted antibody-drug conjugate, in an early-stage trial involving individuals with progressive solid malignancies.

CHS-1000, an Innovative ILT4 Antagonist Antibody, Showcased Through Early-Stage Research at AACR's 2024 Gathering.

Vivet Therapeutics Administers Initial Dose to First Participant in Second Group of Phase 1/2 GATEWAY Study for Wilson Disease Therapy.

Promising Early Results for SCB-1019 Vaccine in Young Adults: Clover Biopharmaceuticals Phase I Insights.

Ichnos Glenmark Innovation Unveils Early Findings for Cancer Candidate ISB 2001 at AACR 2024.

Mabwell has declared that its fully-owned subsidiary, T-mab, has successfully received the green light for its Denosumab Injection from the National Medical Products Administration.

Primary Objectives Achieved in Stage 3 Trial for HLX14, a Biosimilar Contender to Prolia® and Xgeva® (denosumab).

Ferring Unveils Key Phase 3 Results for Experimental Therapy, SI-6603 (condoliase), in Treating Lower Back Disc Protrusion during ASIPP 2024.

U.S. Sanctions ENHERTU®, a Pioneer HER2-Targeting Drug, for Metastatic Solid Cancers with HER2 Positivity After Initial Treatments.

FDA Clears Abecma from Bristol Myers and 2seventy bio for Treatment of Relapsed or Stubborn Multiple Myeloma Following Two Previous Therapies.

Immunome, Inc. plans to reveal early data on IM-3050, their lead drug featuring lutetium-177, targeting the fibroblast activation protein.

Werewolf Therapeutics Reveals Early Stage Study Outcomes Highlighting the Cancer-Fighting Capabilities of Immune-Stimulating Drugs WTX-518 and WTX-712.